GlassScriptPhysician profile
Franklin S Cline
NPI 1720020704
$458,372.07
in general payments reported to CMS, 2019-2025
25 companies · $111K in 2025
The $111K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55K · 2022: $79K · 2023: $101K · 2024: $112K · 2025: $111K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $244K · Travel and Lodging: $60K · Food and Beverage: $11K · Consulting Fee: $8,317 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $244,255.00 |
| Travel and Lodging | $59,887.05 |
| Food and Beverage | $11,318.17 |
| Consulting Fee | $8,316.96 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $445,174.14 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Janssen Scientific Affairs, LLC | $8,772.44 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,699.49 | 2021-2025 | Abilify Asimtufii, Rexulti |
| Abbvie INC. | $379.74 | 2021-2025 | |
| Amgen INC. | $278.93 | 2025 | Tepezza, Krystexxa |
| Genzyme Corporation | $228.92 | 2024-2025 | |
| Alkermes, INC. | $220.47 | 2024-2025 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.52 | 2024-2025 | Caplyta |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $165.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $149.03 | 2022-2024 | Uzedy, Austedo |
| Alcresta Therapeutics, INC. | $122.31 | 2023 | Relizorb |
| Phathom Pharmaceuticals, INC. | $114.83 | 2025 | Voquezna |
| Mannkind Corporation | $106.23 | 2023 | Afrezza |
| Neurocrine Biosciences, INC. | $103.38 | 2022-2024 | Ingrezza |
| Incyte Corporation | $103.00 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $100.00 | 2022 | |
| Sunovion Pharmaceuticals INC. | $87.47 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $81.41 | 2025 | Cobenfy |
| Lundbeck LLC | $73.82 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $69.68 | 2022-2025 | Trintellix |
| Indivior INC. | $66.87 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.66 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $29.97 | 2023 | Fanapt |
| Novo Nordisk INC | $23.63 | 2024 | |
| Pfizer INC. | $20.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.